- Home
- ILAG vs CYCC Comparison
ILAG vs CYCC Comparison
Compare ILAG & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- CYCC
- Stock Information
- Founded
- ILAG 1981
- CYCC 1992
- Country
- ILAG Hong Kong
- CYCC Malaysia
- Employees
- ILAG N/A
- CYCC N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- CYCC Health Care
- Exchange
- ILAG Nasdaq
- CYCC Nasdaq
- Market Cap
- ILAG 9.4M
- CYCC 7.8M
- IPO Year
- ILAG 2022
- CYCC N/A
- Fundamental
- Price
- ILAG $0.51
- CYCC $3.75
- Analyst Decision
- ILAG
- CYCC
- Analyst Count
- ILAG 0
- CYCC 0
- Target Price
- ILAG N/A
- CYCC N/A
- AVG Volume (30 Days)
- ILAG 427.2K
- CYCC 465.6K
- Earning Date
- ILAG 07-22-2025
- CYCC 08-13-2025
- Dividend Yield
- ILAG N/A
- CYCC N/A
- EPS Growth
- ILAG N/A
- CYCC N/A
- EPS
- ILAG N/A
- CYCC N/A
- Revenue
- ILAG $7,506,551.00
- CYCC $14,000.00
- Revenue This Year
- ILAG N/A
- CYCC $137.21
- Revenue Next Year
- ILAG N/A
- CYCC N/A
- P/E Ratio
- ILAG N/A
- CYCC N/A
- Revenue Growth
- ILAG 16.50
- CYCC N/A
- 52 Week Low
- ILAG $0.34
- CYCC $3.08
- 52 Week High
- ILAG $1.35
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- ILAG 51.90
- CYCC 28.20
- Support Level
- ILAG $0.49
- CYCC $3.17
- Resistance Level
- ILAG $0.52
- CYCC $3.97
- Average True Range (ATR)
- ILAG 0.05
- CYCC 0.59
- MACD
- ILAG -0.01
- CYCC 1.36
- Stochastic Oscillator
- ILAG 41.32
- CYCC 36.48
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.